SCHEMBL27081777

SCHEMBL27081777

CN1CCN(Cc2ccc(NC(=O)c3ccc4c(c3)N(Cc3cnc5[nH]nc(N6CCOCC6)c5c3)CC4)cc2C(F)(F)F)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.53
▸ KDR P35968 2/20 0.53
▸ ABL1 P00519 8/20 0.52
▸ RET P07949 2/20 0.52
▸ PDGFRB P09619 1/20 0.52
▸ SRC P12931 1/20 0.52
▸ PDGFRA P16234 1/20 0.52
▸ FLT1 P17948 1/20 0.52
▸ FGFR2 P21802 1/20 0.52
▸ FGFR4 P22455 1/20 0.52
▸ FGFR3 P22607 1/20 0.52
▸ EGFR P00533 9/20 0.51
▸ BRAF P15056 9/20 0.51
▸ BCR P11274 5/20 0.49
▸ KIT P10721 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081498 0.89 ABL1 (0.58) FGFR1ABL1PDGFRAEGFRBRAF
SCHEMBL29967913 0.89 ABL1 (0.58) FGFR1ABL1PDGFRAEGFRBRAF
SCHEMBL27081695 0.89 ABL1 (0.54) FGFR1ABL1PDGFRAEGFRBRAF
SCHEMBL29967530 0.89 ABL1 (0.54) FGFR1ABL1PDGFRAEGFRBRAF
SCHEMBL27081727 0.85 ABL1 (0.53) ABL1EGFRBRAFBCRKIT
SCHEMBL29968011 0.85 ABL1 (0.53) ABL1EGFRBRAFBCRKIT
SCHEMBL27083097 0.84 EGFR (0.68) FGFR1ABL1PDGFRAEGFRBRAF
SCHEMBL27083161 0.83 BRAF (0.68) ABL1RETEGFRBRAFBCR
SCHEMBL27082256 0.82 BRAF (0.58) ABL1RETEGFRBRAFBCR
SCHEMBL27083160 0.82 BRAF (0.68) ABL1EGFRBRAFBCRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP disclosed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN disclosed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 FGFR1 711/4885KDR 137/4885ABL1 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback